Healthcare services company Chemed Corporation (NYSE: CHE) met Wall Streets revenue expectations in Q3 CY2025, with sales up 3.1% year on year to $624.9 million. Its non-GAAP profit of $5.27 per share was 1.8% below analysts’ consensus estimates.

Is now the time to buy CHE? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Chemed’s third quarter was marked by continued operational challenges in both the VITAS and Roto-Rooter businesses, resulting in a negative market reaction. Management attributed the margin compression to higher costs associated with increased hospital-based admissions at VITAS and a shift toward paid leads in Roto-Rooter, which elevated expenses and weighed on profitability. CEO Kevin McNamara pointed to stabilization in VITAS’s Medicare Cap exposure and highlighted a “high watermark” in hospital admission ratios, while also noting that Roto-Rooter’s residential plumbing campaign yielded encouraging results. CFO Michael Witzeman described the quarter’s gross margin as “exactly in line with our guidance,” but acknowledged that segment margins remain below long-term targets.

Looking forward, Chemed’s outlook is shaped by expectations of seasonal strength in Q4 and ongoing efficiency initiatives in both segments. Management believes the strategic focus on hospital admissions will allow VITAS to avoid Medicare Cap billing limits in Florida during 2026, while operational discipline and targeted marketing investments are expected to improve Roto-Rooter’s margins. Witzeman emphasized, “Fourth quarter is always their best quarter,” referring to anticipated rate increases and favorable seasonal trends. CEO McNamara expressed confidence that both businesses are “on the way to returning to a predictable, sustainable growth trajectory,” contingent on continued execution and favorable market dynamics.

Key Insights from Management’s Remarks

Management cited higher hospital-based admissions at VITAS and costlier paid lead generation at Roto-Rooter as the main drivers of margin pressure, while initiatives in patient mix and operational efficiency began to show results.

• VITAS hospital admission strategy: Management increased the proportion of hospital-based admissions to 44.5%, aiming for a more sustainable patient mix and reduced Medicare Cap risks in Florida. This shift led to more short-stay patients, impacting average length of stay and margin but improving Cap management.
• Operational efficiency at VITAS: Internal labor management initiatives and targeted cost reductions helped offset some margin pressure. The team reported SG&A expense reductions and more efficient program staffing, particularly in the Florida market, where regulatory risk is highest.
• Roto-Rooter paid lead focus: The business experienced a continued decline in unpaid (organic) leads, compensated by an 8.6% increase in paid leads. This change elevated SG&A costs and put pressure on margins, but also signaled a possible easing of competition from private equity-backed rivals.
• Residential plumbing momentum: A targeted campaign in residential plumbing—using internet-focused marketing and enhanced sales materials—resulted in an 8.2% lift in that service line, marking a reversal from prior periods of stagnation.
• Margin stabilization efforts: Management implemented tighter field discounting controls and higher approval thresholds to combat margin erosion in Roto-Rooter. While year-to-date margins lag historic levels, leaders expect continued improvement as operational changes take hold.

Drivers of Future Performance

Chemed’s forward guidance centers on seasonal Q4 strength, continued focus on patient mix, and targeted cost management to restore segment margins.

• Q4 seasonal tailwinds: Management expects both VITAS and Roto-Rooter to benefit from typical fourth-quarter dynamics—rate increases for VITAS and weather-driven demand for Roto-Rooter—leading to margin improvement and higher overall profitability.
• Strategic patient mix at VITAS: The company aims to maintain hospital admissions within a 42–45% range, balancing Medicare Cap mitigation with efforts to gradually reintroduce longer-stay, higher-margin patients as regulatory risk abates. This transition is expected to support both revenue growth and EBITDA margin recovery.
• Operational discipline at Roto-Rooter: Continued investment in paid lead generation is intended to drive revenue growth, but management is also implementing controls on technician discounting and focusing on maximizing revenue per lead. Over time, these efforts are projected to lift EBITDA margins back toward the 25–26% target range.

Catalysts in Upcoming Quarters

Looking ahead, our analysts will be monitoring (1) whether VITAS can sustain its hospital admission ratio and avoid Medicare Cap limitations in Florida, (2) margin recovery progress at Roto-Rooter amid higher marketing spend, and (3) the ramp-up of new program launches, such as the Pinellas County location. Developments in lead generation effectiveness and operational improvements will also be key indicators of business momentum.

Chemed currently trades at $466.73, up from $439.05 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free for active Edge members).

Stocks That Trumped Tariffs

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.